On Tuesday, after a year and a half of negotiations over an intellectual property waiver for Covid-related products, the United States, European Union, India and South Africa reportedly reached agreement on a temporary waiver of patent rules for Covid vaccines. Global health activists, however, are slamming the tentative deal as not only insufficient, but a potential setback, because it excludes tests and treatments, includes a carveout for China, and introduces new barriers for the production of generic treatments that could have implications far beyond the Covid crisis.

The post New “Compromise” On IP Waiver For Covid Vaccines Is Worse Than No Deal, Activists Say appeared first on PopularResistance.Org.

This post was originally published on PopularResistance.Org.